Gain Therapeutics (GANX) Director Islam Khalid Receives 25,000-Share Option Award

What Happened Islam Khalid, a director of Gain Therapeutics, was granted a derivative award on 2026-07-15 for 25,000 shares. The Form 4 reports an acquisition at $0.00 (derivative), indicating an option/award rather than an open‑market purchase or sale. The filing (Accession 0001104659-26-084437) was submitted on 2026-07-17.

Key Details

• Transaction date: 2026-07-15; Form 4 filed: 2026-07-17 (timely within typical 2‑business‑day window).
• Instrument: Derivative award/option for 25,000 shares; reported acquisition price $0.00 on the form.
• Vesting: Option vests in 12 equal monthly installments beginning July 24, 2026 (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Vesting is subject to the reporting person’s continuous service through each vesting date.

Context This was a grant of a derivative award (an option-like award) that will convert into ownership only as it vests and, depending on plan terms, upon exercise. Grants are routine compensation for directors and do not reflect an immediate cash investment or sale.